HiberCell, Inc.
New York, NY, US· latest recorded location
HiberCell, Inc. is named on 11 US grants and 25 published applications in this corpus. Its most frequent classification is A61P (Therapeutic uses of medicines).
- Granted patents
- 11
- Published applications
- 25
- Inventors
- 54
- Granted in 2026 so far
- 0
- Most recent grant
- 18 Nov 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2020 | 0 | 1 |
| 2021 | 0 | 4 |
| 2022 | 3 | 8 |
| 2023 | 3 | 1 |
| 2024 | 2 | 5 |
| 2025 | 3 | 4 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 36 documents
- A61PTherapeutic uses of medicines33
- C07DHeterocyclic compounds21
- A61KMedicines and medical preparations20
- C07KPeptides12
- G01NInvestigating or analysing materials by determining their chemical or physical properties8
- C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen7
- C07BGeneral methods of organic chemistry2
- C12NMicroorganisms or enzymes2
Recent patents
- Perk inhibiting compounds18 Nov 2025US 12,473,296 B2
- Methods for identifying beta-glucan binding to immune cells19 Aug 2025US 12,390,526 B2
- Perk inhibiting imidazolopyrazine compounds17 Jun 2025US 12,331,054 B2
- Aminopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitors11 Jun 2024US 12,006,332 B2
- Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors5 Mar 2024US 11,919,902 B2
- Crystalline forms of (r)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)-n-isopropylnicotinamide and methods for using the same10 Sep 2026US 2026/0265199 A1
- Crystalline forms of 6-(3-((5-chloro-2-methoxypyridine)-3-sulfonamido)-2,6-difluorophenyl)-n-methylimidazo[1,5-a]pyrazine-1-carboxamide and methods for using the same6 Aug 2026US 2026/0224563 A1
- Gcn2 modulator for treating cancer6 Nov 2025US 2025/0339426 A1
- Beta-glucan methods and compositions that affect the tumor microenvironment10 Apr 2025US 2025/0114391 A1
- Beta-glucan in combination with anti-cancer agents affecting the tumor micrenvironment10 Apr 2025US 2025/0114392 A1
Most cited
By later US patents